Areas of expertise
Areas of interest
Which type of pharmacy do you work in?
What industry do you work in?
Influencer Of
Experts Like Mohinder Hunjan
Content From Similar Experts
Cookies
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Recent Comments
Previous
What is considered a high dose?I am more confident in providing BP measurement services for the patients who visit the Pharmacy after studying this module
Following
Different therapeutic approaches are used for the treatment of ACS, as platelet-rich clots are found in patients with UA and NSTEMI, while fibrin-rich clots are found in patients with STEMI.
In UA and NSTEMI, the goal of antithrombotic therapy is to prevent further thrombosis and allow the process of endogenous fibrinolysis (the enzymatic breakdown of the fibrin in blood clots) to dissolve the thrombus and reduce the degree of arterial narrowing. Surgical revascularisation is frequently used to increase blood flow and prevent further occlusion or recurrent ischaemia.
In contrast, with STEMI, the artery is usually totally occluded (obstructed), and immediate thrombolytic medicines or catheter-based reperfusion is the initial approach. The goal of these treatment options is to obtain normal coronary blood flow. Other therapies, such as anti-ischaemic and lipid-lowering therapies, are used in all cases in the patient’s long-term treatment plan.
UA and NSTEMI are managed in a similar way, with treatment providing supportive care and pain relief during the acute attack, with the aim of preventing further cardiac events and death. The need for long-term treatment should also be assessed, as most patients will require standard angina t
The aim of treatment in AF is to restore satisfactory circulation, relieve symptoms and prevent further episodes of poor circulation and distress. This can be done by either controlling the ventricular rate – known as ‘rate control’ – or attempting to restore and maintain sinus rhythm – called ‘rhythm control’.
NICE recommends rate control as the first-line strategy for people with AF, offering either a standard beta-blocker – although not sotalol as it may prolong the QT interval and cause life-threatening ventricular arrhythmias – or a rate-limiting calcium channel blocker – such as diltiazem and verapamil.
In addition, a possible third option could be to stop the patient’s current beta-blocker and administer intravenous esmolol, a relatively cardioselective beta-blocker with a very short duration of action, or even metoprolol given its short half-life. If Mr Carlton is in distress he should be treated as soon as possible – via an intravenous route.